Updated overall survival from Herceptin

[tousled1]

Genentech Reports Updated Overall Survival Data From Herceptin Adjuvant Studies In HER2-Positive Breast Cancer - Quick Facts [DNA]

6/4/2007 10:11:05 AM Genentech Inc. (DNA) announced updated results from a joint analysis of two Phase III clinical trials studying Herceptin (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer.

The two randomized, controlled Phase III studies evaluated four cycles of doxorubicin and cyclophosphamide followed by paclitaxel, either every three weeks or weekly for 12 weeks, compared with the same regimens plus 52 weeks of Herceptin in nearly 4,000 patients with HER2-positive breast cancer.

The results showed that the addition of Herceptin to standard adjuvant therapy continued to significantly reduce the risk of breast cancer recurrence, the primary endpoint of the studies, by 52 percent in women with HER2-positive, node-positive breast cancer, compared to patients who received standard adjuvant therapy alone.

At four years of follow-up, 85.9% of women treated with Herceptin plus chemotherapy were disease free, compared to 73.1 percent of women treated with chemotherapy alone.